Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-MPPF is a **fluorine-18 labeled positron emission tomography radioligand** used to image brain **serotonin 1A receptors** in vivo. It is an arylpiperazine-based small-molecule tracer that binds selectively and reversibly to the **5-hydroxytryptamine receptor 1A**, enabling PET quantification of regional receptor distribution and binding potential rather than delivering a direct therapeutic effect. In the context provided here, it is being developed by **Hospices Civils de Lyon** as an investigational imaging agent for PET-MRI studies in **Dravet syndrome** and **drug-resistant focal epilepsy**, with the goal of characterizing serotonergic pathway abnormalities in these disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18F-MPPF.